Fundraising FoxRA Capital — 2021 Investments
25 investments dated 2021 · listed companies and verified rows first · show all
Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.
BiotechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)
Co-investorsGV (Google Ventures)Fidelity InvestmentsForesite CapitalMithril Capital ManagementOmega FundsOrbiMed+3 more
Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.
AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US
Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)inBrent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)Chad Cowan(Chief Scientific Officer)in
BoardToshikazu Ban(Director)
Co-investorsLifeSci Venture PartnersCasdin CapitalVersant Ventures
Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.
BiotechMedical DevicesSolana Beach, US
Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)
BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)
Co-investorsAvoro Capital AdvisorsQuan CapitalSR One Capital ManagementWellington ManagementWestRiver GroupQuan Venture
Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.
BiotechWilmington, US
Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)
BoardAdam Rosenberg(Director)
Co-investorsManta Ray VenturesAccess BiotechnologyACORN BIOVENTURESIntermediate Capital GroupLifeArc Ventures
Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.
BiotechHealthtech
Co-investorsBain Capital Life SciencesForesite CapitalMRL Ventures FundPremji InvestGV (Google Ventures)Mithril Capital Management+2 more
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)Brett Staahl(Founder)
Co-investorsAndreessen HorowitzOrbiMedAvoro Capital AdvisorsMenlo VenturesWellington ManagementAvoro Ventures
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.
BiotechHealthtechSan Diego, US
Vijaya Pattabiraman(Founder)inJeffrey Bode(Founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)
Co-investorsJohnson & Johnson Innovation – JJDCVersant VenturesVenrockAlexandriaBlackRockFidelity Investments+2 more
Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Peter Blume-Jensen(Executive Officer, Director)Kristina Masson(Executive Officer, Director)erick gamelininEric Devroe(Executive Officer)in
BoardMarcin Czernik(Director)Sharon Shacham(Director)
Board seatDerek DiRocco· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)Pureos BioventuresWellington Management
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)
BoardJonathan Leff(Director)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsNextech InvestOrbiMedSR One Capital ManagementSofinnova Ventures
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)inDaniel Becker(Director)
Board seatDerek DiRocco· per SEC Form D · $130M raise · filed Feb 2021
Co-investorsAccess BiotechnologyAtlas VentureCanaan PartnersViking GlobalAccess IndustriesThe Column Group
Vaccine development platform using computationally designed synthetic virus-like particles
BiotechSeattle, US
Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsQiming Venture Partners USASanofi VenturesViking GlobalQiming HealthcareQiming Venture Partners
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak Health+8 more
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)
Co-investorsARCH Venture PartnersEaston CapitalSanofi VenturesThink+ Ventures Management, LlcWakestream VenturesForbion+1 more
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesLightstone VenturesOUP (Osage University Partners)Shah Family OfficeAlly Bridge GroupDe Novo Ventures+4 more
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
David Olson(Founder)David Olson Nick Haft(Founder)Nick Haft(Founder)
Co-investorsArtis VenturesBailey Venture PartnersCasa Verde CapitalDolby Family VenturesNoeticOMX Ventures+6 more
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesFelicis VenturesMPM BioImpactDCVC Bio+2 more
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundOUP (Osage University Partners)Pfizer Venture InvestmentsQuan Capital+4 more
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsEcoR1 CapitalHBM Healthcare InvestmentsHBM PartnersLAVLilly Asia VenturesSamsara BioCapital+3 more
Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.
Deep TechEnergyHardware
Michael Gorman(Founder)in
Co-investorsFoothill VenturesAccess BiotechnologyAtlas VentureBain Capital Life SciencesBiotechnology Value FundCommodore Capital+2 more
FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.
AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US
Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)
Co-investorsPre-Seed to SucceedYellow Rocks!Access BiotechnologyAtlas VentureBain Capital Life SciencesBiotechnology Value Fund+3 more
Nucleix is a healthcare company developing diagnostic technology based on DNA/nucleic acid analysis for cancer detection.
BiotechDigital HealthHealthtechMedical Devices
Eli Frydman(President EMEA)
Co-investorsGefen CapitalOrbiMedAurum Ventures MKIBlackRockLilly Asia VenturesLYFE Capital+1 more
Thriveworks provides therapy and psychiatric medication management services, helping clients find providers and book sessions, with insurance accepted.
Digital HealthHealthtechMedia & EntertainmentMental HealthWellness & Fitness
Anthony Centore(Executive Officer, Director)Jon Santemma(Executive Officer, Director)Terry Wang(Director)David Kim(Director)
Co-investorsRogue Insight CapitalTRANSFORMATION CAPITALWellington ManagementFidelity InvestmentsREDMILE
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Founder)inAndrew Bellinger(Executive Officer)Kiran Musunuru(Founder)
BoardJohn Evans(Director)Anthony Philippakis(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)venBio PartnersWellington ManagementCasdin Capital+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.